The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.

Kamada begins patient enrolment in an investigator-initiated clinical trial of Cytogam to prevent cytomegalovirus in kidney transplantation: Rehovot, Israel Thursday, November 6, ...

Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...